Literature DB >> 34291395

Omeprazole suppresses endothelial calcium response and eNOS Ser1177 phosphorylation in porcine aortic endothelial cells.

Chiaki Kamiya1, Keiichi Odagiri2, Akio Hakamata1, Ryugo Sakurada1, Naoki Inui1, Hiroshi Watanabe1.   

Abstract

BACKGROUND: Although high doses of proton pump inhibitors can elicit an anticancer effect, this strategy may impair vascular biology. In particular, their effects on endothelial Ca2+ signaling and production of endothelium-derived relaxing factor (EDRF) are unknown. To this end, we investigated the effects of high dosages of omeprazole on endothelial Ca2+ responses and EDRF production in primary cultured porcine aortic endothelial cells. METHODS AND
RESULTS: Omeprazole (10-1000 μM) suppressed both bradykinin (BK)- and thapsigargin-induced endothelial Ca2+ response in a dose-dependent manner. Furthermore, omeprazole slightly attenuated Ca2+ mobilization from the endoplasmic reticulum, whereas no inhibitory effects on endoplasmic reticulum Ca2+-ATPase were observed. Omeprazole decreased BK-induced phosphorylation of endothelial nitric oxide synthase (eNOS) at Ser1177 and tended to decrease BK-induced nitric oxide production. Production of prostaglandin I2 metabolites, especially 6-keto-prostaglandin 1α, also tended to be reduced by omeprazole.
CONCLUSION: Our results are the first to indicate that high doses of omeprazole may suppress both store-operated Ca2+ channels and partially the G protein-coupled receptor/phospholipase C/inositol 1,4,5-triphosphate pathway, and decreased BK-induced, Ca2+-dependent phosphorylation of eNOS(Ser1177). Thus, high dosages of omeprazole impaired EDRF production by attenuating intracellular Ca2+ signaling.
© 2021. The Author(s), under exclusive licence to Springer Nature B.V.

Entities:  

Keywords:  Calcium; Endothelial cells; Endothelium-dependent relaxing factors; Nitric oxide synthase; Omeprazole

Mesh:

Substances:

Year:  2021        PMID: 34291395     DOI: 10.1007/s11033-021-06561-0

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  40 in total

Review 1.  Role of proton pump inhibitors in preventing hypergastrinemia-associated carcinogenesis and in antagonizing the trophic effect of gastrin.

Authors:  Y-M Han; J-M Park; N Kangwan; M Jeong; S Lee; J Y Cho; W J Ko; K B Hahm
Journal:  J Physiol Pharmacol       Date:  2015-04       Impact factor: 3.011

2.  Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease.

Authors:  Benjamin Lazarus; Yuan Chen; Francis P Wilson; Yingying Sang; Alex R Chang; Josef Coresh; Morgan E Grams
Journal:  JAMA Intern Med       Date:  2016-02       Impact factor: 21.873

3.  A new mechanism for anti-inflammatory actions of proton pump inhibitors--inhibitory effects on neutrophil-endothelial cell interactions.

Authors:  N Yoshida; T Yoshikawa; Y Tanaka; N Fujita; K Kassai; Y Naito; M Kondo
Journal:  Aliment Pharmacol Ther       Date:  2000-04       Impact factor: 8.171

4.  Proton Pump Inhibitors Accelerate Endothelial Senescence.

Authors:  Gautham Yepuri; Roman Sukhovershin; Timo Z Nazari-Shafti; Michael Petrascheck; Yohannes T Ghebre; John P Cooke
Journal:  Circ Res       Date:  2016-05-10       Impact factor: 17.367

5.  Unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine.

Authors:  Yohannes T Ghebremariam; Paea LePendu; Jerry C Lee; Daniel A Erlanson; Anna Slaviero; Nigam H Shah; James Leiper; John P Cooke
Journal:  Circulation       Date:  2013-07-03       Impact factor: 29.690

6.  Use of proton pump inhibitors as adjunct treatment for triple-negative breast cancers. An introductory study.

Authors:  Wayne Goh; Inna Sleptsova-Freidrich; Nenad Petrovic
Journal:  J Pharm Pharm Sci       Date:  2014       Impact factor: 2.327

7.  Intermittent high dose proton pump inhibitor enhances the antitumor effects of chemotherapy in metastatic breast cancer.

Authors:  Bi-Yun Wang; Jian Zhang; Jia-Lei Wang; Si Sun; Zhong-Hua Wang; Lei-Ping Wang; Qun-Ling Zhang; Fang-Fang Lv; En-Ying Cao; Zhi-Min Shao; Stefano Fais; Xi-Chun Hu
Journal:  J Exp Clin Cancer Res       Date:  2015-08-22

8.  The aryl hydrocarbon receptor ligand omeprazole inhibits breast cancer cell invasion and metastasis.

Authors:  Un-Ho Jin; Syng-Ook Lee; Catherine Pfent; Stephen Safe
Journal:  BMC Cancer       Date:  2014-07-09       Impact factor: 4.430

9.  Proton-pump inhibitor omeprazole attenuates hyperoxia induced lung injury.

Authors:  Jute Richter; Julio Jimenez; Taro Nagatomo; Jaan Toelen; Paul Brady; Thomas Salaets; Flore Lesage; Jeroen Vanoirbeek; Jan Deprest
Journal:  J Transl Med       Date:  2016-08-27       Impact factor: 5.531

10.  Omeprazole impairs vascular redox biology and causes xanthine oxidoreductase-mediated endothelial dysfunction.

Authors:  Lucas C Pinheiro; Gustavo H Oliveira-Paula; Rafael L Portella; Danielle A Guimarães; Celio D de Angelis; Jose E Tanus-Santos
Journal:  Redox Biol       Date:  2016-08-04       Impact factor: 11.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.